Mechanisms Explaining Muscle Fatigue and Muscle Pain in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a Review of Recent Findings

Recently published papers of particular interest have been highlighted as: • Of importance

1. 1.
   Brurberg KG, Fonhus MS, Larun L, Flottorp S, Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open. 2014;4(2):e003973.PubMedPubMedCentralCrossRefGoogle Scholar
2. 2.
   Sharpe M, Archard L, Banatvala J, Borysiewicz L, Clare A, David A. A report-chronic fatigue syndrome: guidelines for research. J R Soc Med. 1991;84:118–21.PubMedPubMedCentralCrossRefGoogle Scholar
3. 3.
   Carruthers B, van de Sande M, De Meirleir K, Klimas N, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270:327–38.PubMedPubMedCentralCrossRefGoogle Scholar
4. 4.
   Jason LA, Brown A, Clyne E, Bartgis L, Evans M, Brown M. Contrasting case definitions for chronic fatigue syndrome, myalgic encephalomyelitis/chronic fatigue syndrome and myalgic encephalomyelitis. Eval Health Prof. 2012;35(3):280–304.PubMedCrossRefGoogle Scholar
5. 5.
   Jason LA, Kot B, Sunnquist M, Brown A, Evans M, Jantke R, et al. Chronic fatigue syndrome and myalgic encephalomyelitis: toward an empirical case definition. Health Psychol Behav Med. 2015;3(1):82–93.PubMedPubMedCentralCrossRefGoogle Scholar
6. 6.
   Jason LA, McManimen S, Sunnquist M, Brown A, Furst J, Newton JL, et al. Case definitions integrating empiric and consensus perspectives. Fatigue : Biomed, Health Behav. 2016;4(1):1–23.Google Scholar
7. 7.
   Morris G, Maes M. Case definitions and diagnostic criteria for myalgic encephalomyelitis and chronic fatigue syndrome: from clinical-consensus to evidence-based case definitions. Neuro Endocrinol Lett. 2013;34:185–99.PubMedGoogle Scholar
8. 8.
   • Morris G, Berk M, Galecki P, Walder K, Maes M. The neuro-immune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. Mol Neurobiol. 2015;53(2):1195–219. This paper reviews pathways and abnormalities underpinning the incapacitating fatigue suffered by many people suffering from a range of systemic and neuro-inflammatory disorders including ME/CFS.Google Scholar
9. 9.
   Shan ZY, Kwiatek R, Burnet R, Del Fante P, Staines DR, Marshall-Gradisnik SM, et al. Progressive brain changes in patients with chronic fatigue syndrome: a longitudinal MRI study. J Magn Reson Imaging. 2016.Google Scholar
10. 10.
    Barnden LR, Crouch B, Kwiatek R, Burnet R, Del Fante P. Evidence in chronic fatigue syndrome for severity-dependent upregulation of prefrontal myelination that is independent of anxiety and depression. NMR Biomed. 2015;28(3):404–13.PubMedPubMedCentralCrossRefGoogle Scholar
11. 11.
    Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015;1(1).Google Scholar
12. 12.
    • Russell L, Broderick G, Taylor R, Fernandes H, Harvey J, Barnes Z, et al. Illness progression in chronic fatigue syndrome: a shifting immune baseline. BMC Immunol. 2016;17(1):1–11. This study involved patients diagnosed with ME/CFS according to very narrow criteria and the authors reported longitudinal changes in their immune profile with elevated levels of IL-8 in the recently afflicted but the opposite held in patients ill for more than 2 years. Similarly, early ME/CFS patients displayed low levels of IL-6 but the reverse was true in patients suffering from incapacitating fatigue for over 2 years.Google Scholar
13. 13.
    Kerr JR. Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Curr Rheumatol Rep. 2008;10(6):482–91.PubMedCrossRefGoogle Scholar
14. 14.
    Jason LA, Corradi K, Torres-Harding S, Taylor RR, King C. Chronic fatigue syndrome: the need for subtypes. Neuropsychol Rev. 2005;15(1):29–58.PubMedCrossRefGoogle Scholar
15. 15.
    Zhang L, Gough J, Christmas D, Mattey DL, Richards SCM, Main J, et al. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol. 2010;63(2):156–64.PubMedCrossRefGoogle Scholar
16. 16.
    Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatr. 2014;5:98.CrossRefGoogle Scholar
17. 17.
    • Maes M. A new case definition of neuro-inflammatory and oxidative fatigue (NIOF), a neuroprogressive disorder, formerly known as chronic fatigue syndrome or myalgic encephalomyelitis: results of multivariate pattern recognition methods and external validation by neuro-immune biomarkers. Neuro Endocrinol Lett. 2015;36(4):320–9. This paper provides evidence demonstrating that ME/CFS is not a single illness with a unitary pathogenesis and pathophysiology. This paper outlines a new diagnostic schema offering a pathway to selecting a “subgroup ” of CFS patients which could form the basis of testing many of the explanations proposed to underpin the well-documented muscle pathology seen in many patients who have been afforded a CFS diagnosis.Google Scholar
18. 18.
    Maes M, Twisk FN, Johnson C. Myalgic encephalomyelitis (ME), chronic fatigue syndrome (CFS), and chronic fatigue (CF) are distinguished accurately: results of supervised learning techniques applied on clinical and inflammatory data. Psychiatry Res. 2012;200(2-3):754–60.PubMedCrossRefGoogle Scholar
19. 19.
    • Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiomed. 2016;4(1):1–12. This is an important study as it builds on earlier work demonstrating the existence of intestinal dysbiosis in many CFS patients. This is significant as it potentially explains the presence of commensal antigens in the periheral blood of ME/CFS patients repeatedly reported by researchers. The chronic activation of pattern recognition receptors such as TLR-4 by bacterial antigens translocated from the gut could go some way to explaining the presence of activated inflammatory pathways and chronic O&NS in ME/CFS patients diagnosed according to international consensus guidelines.Google Scholar
20. 20.
    • Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D, et al. Changes in gut and plasma microbiome following exercise challenge in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). PLoS One. 2015;10(12):e0145453. This study provided an avenue whereby patients with disuse muscle deconditioning could be differentiated from patients with ME/CFS as these changes in the commensal population and plasma LPS levels with exercise have not been reported in the former group of people. This increase in systemic markers of inflammation can also go some way to explaining the phenomenon of a worsening of global symptoms during and in the immediate aftermath of very slight increases in physical activity.Google Scholar
21. 21.
    Maes M, Twisk FN, Kubera M, Ringel K, Leunis JC, Geffard M. Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J Affect Disord. 2012;136(3):909–17.PubMedCrossRefGoogle Scholar
22. 22.
    Maes M, Mihaylova I, Leunis J-C. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative enterobacteria in the etiology of CFS and for the presence of an increased gut–intestinal permeability. J Affect Disord. 2007;99(1-3):237–40.PubMedCrossRefGoogle Scholar
23. 23.
    • Morris G, Berk M, Klein H, Walder K, Galecki P, Maes M. Nitrosative stress, hypernitrosylation, and autoimmune responses to nitrosylated proteins: new pathways in neuroprogressive disorders including depression and chronic fatigue syndrome. Molec Neurobiol. 2016. This review examines recent studies investigating the adverse effect of dysfunctional nitric oxide signalling effect by reversible S-nitrosylation as a source of pathology. The mechanisms regulating this form of signalling breakdown in an environment of chronic O&NS and such a breakdown could explain in part many of the abnormalities observed in ME/CFS patients in the immunological, autoimmune and bioenergetic domains.Google Scholar
24. 24.
    White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011;377(9768):823–36.PubMedPubMedCentralCrossRefGoogle Scholar
25. 25.
    Sharpe M, Goldsmith KA, Johnson AL, Chalder T, Walker J, White PD. Rehabilitative treatments for chronic fatigue syndrome: long-term follow-up from the PACE trial. Lancet Psychiatr. 2015;2(12):1067–74.CrossRefGoogle Scholar
26. 26.
    Lavergne MR, Cole DC, Kerr K, Marshall LM. Functional impairment in chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivity. Can Fam Physician. 2010;56(2):e57–65.PubMedPubMedCentralGoogle Scholar
27. 27.
    Nacul LC, Lacerda EM, Campion P, Pheby D, Drachler Mde L, Leite JC, et al. The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. BMC Public Health. 2011;11:402.PubMedPubMedCentralCrossRefGoogle Scholar
28. 28.
    Snell CR, Stevens SR, Davenport TE, Van Ness JM. Discriminative validity of metabolic and workload measurements for identifying people with chronic fatigue syndrome. Phys Ther. 2013;93(11):1484–92.PubMedCrossRefGoogle Scholar
29. 29.
    • Keller BA, Pryor JL, Giloteaux L. Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO(2)peak indicates functional impairment. J Transl Med. 2014;12:104. This study shows that repeated cardiopulmonary exercise tests may be employed as a clinical indicator for diagnosing ME/CFS. Moreover, ME/CFS patients are unable to reproduce physiological measures at maximal/ventilatory threshold.Google Scholar
30. 30.
    Jammes Y, Steinberg JG, Delliaux S. Chronic fatigue syndrome: acute infection and history of physical activity affect resting levels and response to exercise of plasma oxidant/antioxidant status and heat shock proteins. J Intern Med. 2012;272(1):74–84.PubMedCrossRefGoogle Scholar
31. 31.
    • Rutherford G, Manning P, Newton JL. Understanding muscle dysfunction in chronic fatigue syndrome. J Aging Res. 2016;2016:2497348. Another mechanism that may explain muscle fatigue in patients with ME/CFS is the overutilisation of the lactate dehydrogenase pathway and slowed acid clearance after exercise.Google Scholar
32. 32.
    Earl K, Sakellariou G, Owens D, Sinclair M, Fenech M, Close G et al. The role of cytokines in muscle fatigue in patients with chronic fatigue syndrome (CFS). The FASEB J. 2015;29(1 Supplement).Google Scholar
33. 33.
    Fukuda K. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953.PubMedCrossRefGoogle Scholar
34. 34.
    He J, Hollingsworth KG, Newton JL, Blamire AM. Cerebral vascular control is associated with skeletal muscle pH in chronic fatigue syndrome patients both at rest and during dynamic stimulation. NeuroImage: Clin. 2013;2:168–73.CrossRefGoogle Scholar
35. 35.
    Nijs J, Aelbrecht S, Meeus M, Van Oosterwijck J, Zinzen E, Clarys P. Tired of being inactive: a systematic literature review of physical activity, physiological exercise capacity and muscle strength in patients with chronic fatigue syndrome. Disabil Rehabil. 2011;33(17-18):1493–500.PubMedCrossRefGoogle Scholar
36. 36.
    Davenport TE, Stevens SR, Baroni K, Van Ness JM, Snell CR. Reliability and validity of short form 36 version 2 to measure health perceptions in a sub-group of individuals with fatigue. Disabil Rehabil. 2011;33(25-26):2596–604.PubMedCrossRefGoogle Scholar
37. 37.
    Davenport TE, Stevens SR, Baroni K, Van Ness M, Snell CR. Diagnostic accuracy of symptoms characterising chronic fatigue syndrome. Disabil Rehabil. 2011;33(19-20):1768–75.PubMedCrossRefGoogle Scholar
38. 38.
    Davenport TE, Stevens SR, VanNess MJ, Snell CR, Little T. Conceptual model for physical therapist management of chronic fatigue syndrome/myalgic encephalomyelitis. Phys Ther. 2010;90(4):602–14.PubMedCrossRefGoogle Scholar
39. 39.
    Dimauro I, Mercatelli N, Caporossi D. Exercise-induced ROS in heat shock proteins response. Free Radical Biology Med. 2016.Google Scholar
40. 40.
    Jammes Y, Steinberg J, Mambrini O, Bregeon F, Delliaux S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med. 2005;257:299–310.PubMedCrossRefGoogle Scholar
41. 41.
    Jammes Y, Steinberg JG, Delliaux S, Bregeon F. Chronic fatigue syndrome combines increased exercise-induced oxidative stress and reduced cytokine and Hsp responses. J Intern Med. 2009;266(2):196–206.PubMedCrossRefGoogle Scholar
42. 42.
    Molvarec A, Rigó J, Lázár L, Balogh K, Makó V, Cervenak L, et al. Increased serum heat-shock protein 70 levels reflect systemic inflammation, oxidative stress and hepatocellular injury in preeclampsia. Cell Stress Chaperones. 2009;14(2):151–9.PubMedCrossRefGoogle Scholar
43. 43.
    McConnell KW, Fox AC, Clark AT, Chang N-YN, Dominguez JA, Farris AB, et al. The role of HSP70 in mediating age-dependent mortality in sepsis. J Immunol (Baltimore, Md : 1950). 2011;186(6):3718–25.CrossRefGoogle Scholar
44. 44.
    Fittipaldi S, Dimauro I, Mercatelli N, Caporossi D. Role of exercise-induced reactive oxygen species in the modulation of heat shock protein response. Free Radic Res. 2014;48(1):52–70.PubMedCrossRefGoogle Scholar
45. 45.
    Senf SM. Skeletal muscle heat shock protein 70: diverse functions and therapeutic potential for wasting disorders. Front Physiol. 2013;4:330.PubMedPubMedCentralCrossRefGoogle Scholar
46. 46.
    Senf SM, Howard TM, Ahn B, Ferreira LF, Judge AR. Loss of the inducible Hsp70 delays the inflammatory response to skeletal muscle injury and severely impairs muscle regeneration. PLoS One. 2013;8(4):e62687.PubMedPubMedCentralCrossRefGoogle Scholar
47. 47.
    Novak ML, Weinheimer-Haus EM, Koh TJ. Macrophage activation and skeletal muscle healing following traumatic injury. J Pathol. 2014;232(3):344–55.PubMedPubMedCentralCrossRefGoogle Scholar
48. 48.
    Hindi SM, Kumar A. Toll-like receptor signalling in regenerative myogenesis: friend and foe. J Pathol. 2016;239(2):125–8.PubMedCrossRefGoogle Scholar
49. 49.
    Whiteside A, Hansen S, Chaudhuri A. Exercise lowers pain threshold in chronic fatigue syndrome. Pain. 2004;109(3):497–9.PubMedCrossRefGoogle Scholar
50. 50.
    Van Oosterwijck J, Nijs J, Meeus M, Lefever I, Huybrechts L, Lambrecht L, et al. Pain inhibition and postexertional malaise in myalgic encephalomyelitis/chronic fatigue syndrome: an experimental study. J Intern Med. 2010;268(3):265–78.PubMedCrossRefGoogle Scholar
51. 51.
    Meeus M, Roussel NA, Truijen S, Nijs J. Reduced pressure pain thresholds in response to exercise in chronic fatigue syndrome but not in chronic low back pain: an experimental study. J Rehabil Med. 2010;42(9):884–90.PubMedCrossRefGoogle Scholar
52. 52.
    Nijs J, Meeus M, Van Oosterwijck J, Ickmans K, Moorkens G, Hans G, et al. In the mind or in the brain? Scientific evidence for central sensitisation in chronic fatigue syndrome. Eur J Clin Invest. 2012;42(2):203–12.PubMedCrossRefGoogle Scholar
53. 53.
    Vecchiet J, Cipollone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett. 2003;335:151–4.PubMedCrossRefGoogle Scholar
54. 54.
    Light A, White A, Hughen R, Light K. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J Pain. 2009;10:1099–112.PubMedPubMedCentralCrossRefGoogle Scholar
55. 55.
    Light AR, Bateman L, Jo D, Hughen RW, Vanhaitsma TA, White AT, et al. Gene expression alterations at baseline and following moderate exercise in patients with chronic fatigue syndrome and fibromyalgia syndrome. J Intern Med. 2012;271(1):64–81.PubMedCrossRefGoogle Scholar
56. 56.
    Nijs J, Nees A, Paul L, De Kooning M, Ickmans K, Meeus M, et al. Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic literature review. Exerc Immunol Rev. 2014;20:94–116.PubMedGoogle Scholar
57. 57.
    Kent-Braun J, Sharma K, Weiner M, Massie B, Miller R. Central basis of muscle fatigue in chronic fatigue syndrome. Neurology. 1993;43:125–31.PubMedCrossRefGoogle Scholar
58. 58.
    Schillings M, Kalkman J, van der Werf S, van Engelen B, Bleijenberg G, Zwartz M. Diminished central activation during maximal voluntary contraction in chronic fatigue syndrome. Clin Neurophysiol. 2004;115:2518–24.PubMedCrossRefGoogle Scholar
59. 59.
    Vermeulen R, Kurk R, Visser F, Sluiter W, Scholte H. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med. 2010;8:93.PubMedPubMedCentralCrossRefGoogle Scholar
60. 60.
    Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med. 2015;13(1):68.PubMedPubMedCentralCrossRefGoogle Scholar
61. 61.
    Morris G, Maes M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 2013;11(1):205.PubMedPubMedCentralCrossRefGoogle Scholar
62. 62.
    • Naviaux RK, Naviaux JC, Li K, Bright AT, Alaynick WA, Wang L, et al. Metabolic features of chronic fatigue syndrome. Proc Natl Acad Sci. 2016;113(37):E5472–80. The authors of this study reported a characteristic pattern of cellular hypometabolism characteristic of impaired mitochondrial function compared to normal subjects which has not been demonstrated in patients suffering from anxiety depression or disuse muscle deconditioning. The authors have proposed that their proteomic signature could provide the first objective test enabling a diagnosis of ME/CFS.Google Scholar
63. 63.
    VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR. Postexertional malaise in women with chronic fatigue syndrome. J Women’s Health (2002). 2010;19(2):239–44.CrossRefGoogle Scholar
64. 64.
    Fulle S, Pietrangelo T, Mancinelli R, Saggini R, Fano G. Specific correlations between muscle oxidative stress and chronic fatigue syndrome: a working hypothesis. J Muscle Res Cell Motil. 2007;28:355–62.PubMedCrossRefGoogle Scholar
65. 65.
    Jones D, Hollingsworth K, Taylor R, Blamire A, Newton J. Abnormalities in pH handling by peripheral muscle and potential regulation by the autonomic nervous system in chronic fatigue syndrome. J Intern Med. 2010;267:394–401.PubMedCrossRefGoogle Scholar
66. 66.
    Jones DE, Hollingsworth KG, Jakovljevic DG, Fattakhova G, Pairman J, Blamire AM, et al. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: a case-control study. Eur J Clin Invest. 2012;42(2):186–94.PubMedCrossRefGoogle Scholar
67. 67.
    Morris G, Maes M. Oxidative and nitrosative stress and immune-inflammatory pathways in patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Curr Neuropharmacol. 2014;12:168–85.PubMedPubMedCentralCrossRefGoogle Scholar
68. 68.
    McCully K, Natelson B. Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clin Sci (Lond). 1999;97:603 - 8.Google Scholar
69. 69.
    Wong R, Lopaschuk G, Zhu G, Walker D, Catellier D, Burton D. Skeletal muscle metabolism in the chronic fatigue syndrome. in vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest. 1992;102:1716–22.PubMedCrossRefGoogle Scholar
70. 70.
    Lane R, Barrett M, Taylor D, Kemp G, Lodi R. Heterogeneity in chronic fatigue syndrome: evidence from magnetic resonance spectroscopy of muscle. Neuromuscul Disord. 1998;8:204–9.PubMedCrossRefGoogle Scholar
71. 71.
    Barnes P, Taylor D, Kemp G, Radda G. Skeletal muscle bioenergetics in the chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 1993;56:679–83.PubMedPubMedCentralCrossRefGoogle Scholar
72. 72.
    Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000;29(12):1252–9.PubMedCrossRefGoogle Scholar
73. 73.
    Reid MB, Moylan JS. Beyond atrophy: redox mechanisms of muscle dysfunction in chronic inflammatory disease. J Physiol. 2011;589(Pt 9):2171–9.PubMedPubMedCentralCrossRefGoogle Scholar
74. 74.
    Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002;166(4):479–84.PubMedCrossRefGoogle Scholar
75. 75.
    Chambers MA, Moylan JS, Reid MB. Physical inactivity and muscle weakness in the critically ill. Crit Care Med. 2009;37(10 Suppl):S337–46.PubMedCrossRefGoogle Scholar
76. 76.
    Chambers MA, Moylan JS, Smith JD, Goodyear LJ, Reid MB. Stretch-stimulated glucose uptake in skeletal muscle is mediated by reactive oxygen species and p38 MAP-kinase. J Physiol. 2009;587(Pt 13):3363–73.PubMedPubMedCentralCrossRefGoogle Scholar
77. 77.
    Michaelson LP, Iler C, Ward CW. ROS and RNS signaling in skeletal muscle: critical signals and therapeutic targets. Annu Rev Nurs Res. 2013;31:367–87.PubMedPubMedCentralCrossRefGoogle Scholar
78. 78.
    Steinbacher P, Eckl P. Impact of oxidative stress on exercising skeletal muscle. Biomolecules. 2015;5(2):356–77.PubMedPubMedCentralCrossRefGoogle Scholar
79. 79.
    Powers SK, Smuder AJ, Judge AR. Oxidative stress and disuse muscle atrophy: cause or consequence? Curr Opin Clin Nutrit Metab Care. 2012;15(3):240–5.CrossRefGoogle Scholar
80. 80.
    Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev. 2008;88(4):1243–76.PubMedPubMedCentralCrossRefGoogle Scholar
81. 81.
    Reid MB. Nitric oxide, reactive oxygen species, and skeletal muscle contraction. Med Sci Sports Exerc. 2001;33(3):371–6.PubMedCrossRefGoogle Scholar
82. 82.
    • Debold EP. Potential molecular mechanisms underlying muscle fatigue mediated by reactive oxygen and nitrogen species. Front Physiol. 2015;6:239. This review highlights some of the recent efforts which may offer information on the underlying molecular basis of muscle fatigue, including increased O&NS. The author discusses that compelling evidence comes from studies showing that pre-treatment of intact muscle with ROS scavengers significantly attenuate O&NS and the development of fatigue. The author concludes that two important emerging sites are the regulatory protein troponin and the actin binding region of myosin.Google Scholar
83. 83.
    Ferreira LF, Reid MB. Muscle-derived ROS and thiol regulation in muscle fatigue. J Appl Physiol. 2008;104(3):853–60.PubMedCrossRefGoogle Scholar
84. 84.
    Fabisiak JP, Ritov VB, Kagan VE. Reversible thiol-dependent activation of ryanodine-sensitive Ca2+ release channel by etoposide (VP-16) phenoxyl radical. Antioxid Redox Signal. 2000;2(1):73–82.PubMedCrossRefGoogle Scholar
85. 85.
    Gutierrez-Martin Y, Martin-Romero FJ, Inesta-Vaquera FA, Gutierrez-Merino C, Henao F. Modulation of sarcoplasmic reticulum Ca(2+)-ATPase by chronic and acute exposure to peroxynitrite. Europ J Biochem / FEBS. 2004;271(13):2647–57.CrossRefGoogle Scholar
86. 86.
    Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Europ J Biochem / FEBS. 2000;267(20):6102–9.CrossRefGoogle Scholar
87. 87.
    Aronson D, Violan MA, Dufresne SD, Zangen D, Fielding RA, Goodyear LJ. Exercise stimulates the mitogen-activated protein kinase pathway in human skeletal muscle. J Clin Invest. 1997;99(6):1251–7.PubMedPubMedCentralCrossRefGoogle Scholar
88. 88.
    Posterino GS, Cellini MA, Lamb GD. Effects of oxidation and cytosolic redox conditions on excitation-contraction coupling in rat skeletal muscle. J Physiol. 2003;547(Pt 3):807–23.PubMedPubMedCentralCrossRefGoogle Scholar
89. 89.
    Smith MA, Reid MB. Redox modulation of contractile function in respiratory and limb skeletal muscle. Respir Physiol Neurobiol. 2006;151(2-3):229–41.PubMedCrossRefGoogle Scholar
90. 90.
    Moopanar TR, Allen DG. Reactive oxygen species reduce myofibrillar Ca2+ sensitivity in fatiguing mouse skeletal muscle at 37 degrees C. J Physiol. 2005;564(Pt 1):189–99.PubMedPubMedCentralCrossRefGoogle Scholar
91. 91.
    Coirault C, Guellich A, Barbry T, Samuel JL, Riou B, Lecarpentier Y. Oxidative stress of myosin contributes to skeletal muscle dysfunction in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2007;292(2):H1009–17.PubMedCrossRefGoogle Scholar
92. 92.
    Yamada T, Mishima T, Sakamoto M, Sugiyama M, Matsunaga S, Wada M. Oxidation of myosin heavy chain and reduction in force production in hyperthyroid rat soleus. J Appl Physiol (1985). 2006;100(5):1520–6.CrossRefGoogle Scholar
93. 93.
    Plant DR, Lynch GS, Williams DA. Hydrogen peroxide modulates Ca2+-activation of single permeabilized fibres from fast- and slow-twitch skeletal muscles of rats. J Muscle Res Cell Motil. 2000;21(8):747–52.PubMedCrossRefGoogle Scholar
94. 94.
    Kaneko M, Suzuki H, Masuda H, Yuan G, Hayashi H, Kobayashi A, et al. Effects of oxygen free radicals on Ca2+ binding to cardiac troponin. Jpn Circ J. 1992;56 Suppl 5:1288–90.PubMedGoogle Scholar
95. 95.
    Powers SK, Ji LL, Kavazis AN, Jackson MJ. Reactive oxygen species: impact on skeletal muscle. Compre Physiol. 2011;1(2):941–69.Google Scholar
96. 96.
    McKenna MJ, Bangsbo J, Renaud J-M. Muscle K+, Na+, and Cl− disturbances and Na+-K+ pump inactivation: implications for fatigue. J Appl Physiol. 2008;104(1):288–95.PubMedCrossRefGoogle Scholar
97. 97.
    Marechal G, Gailly P. Effects of nitric oxide on the contraction of skeletal muscle. Cell Molec Life Sci : CMLS. 1999;55(8-9):1088–102.PubMedCrossRefGoogle Scholar
98. 98.
    Pouvreau S, Allard B, Berthier C, Jacquemond V. Control of intracellular calcium in the presence of nitric oxide donors in isolated skeletal muscle fibres from mouse. J Physiol. 2004;560(Pt 3):779–94.PubMedPubMedCentralCrossRefGoogle Scholar
99. 99.
    Viner RI, Williams TD, Schoneich C. Nitric oxide-dependent modification of the sarcoplasmic reticulum Ca-ATPase: localization of cysteine target sites. Free Radic Biol Med. 2000;29(6):489–96.PubMedCrossRefGoogle Scholar
100. 100.
     Viner RI, Krainev AG, Williams TD, Schoneich C, Bigelow DJ. Identification of oxidation-sensitive peptides within the cytoplasmic domain of the sarcoplasmic reticulum Ca2+-ATPase. Biochemistry. 1997;36(25):7706–16.PubMedCrossRefGoogle Scholar
101. 101.
     Hidalgo C, Sanchez G, Barrientos G, Aracena-Parks P. A transverse tubule NADPH oxidase activity stimulates calcium release from isolated triads via ryanodine receptor type 1 S-glutathionylation. J Biol Chem. 2006;281(36):26473–82.PubMedCrossRefGoogle Scholar
102. 102.
     Hart JD, Dulhunty AF. Nitric oxide activates or inhibits skeletal muscle ryanodine receptors depending on its concentration, membrane potential and ligand binding. J Membr Biol. 2000;173(3):227–36.PubMedCrossRefGoogle Scholar
103. 103.
     Heunks LM, Machiels HA, Dekhuijzen PN, Prakash YS, Sieck GC. Nitric oxide affects sarcoplasmic calcium release in skeletal myotubes. J Appl Physiol (1985). 2001;91(5):2117–24.Google Scholar
104. 104.
     Gehlert S, Bungartz G, Willkomm L, Korkmaz Y, Pfannkuche K, Schiffer T, et al. Intense resistance exercise induces early and transient increases in ryanodine receptor 1 phosphorylation in human skeletal muscle. PLoS One. 2012;7(11):e49326.PubMedPubMedCentralCrossRefGoogle Scholar
105. 105.
     Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med. 2009;15(3):325–30.PubMedPubMedCentralCrossRefGoogle Scholar
106. 106.
     Suhr F, Gehlert S, Grau M, Bloch W. Skeletal muscle function during exercise—fine-tuning of diverse subsystems by nitric oxide. Int J Mol Sci. 2013;14(4):7109–39.PubMedPubMedCentralCrossRefGoogle Scholar
107. 107.
     Boczkowski J, Lisdero C, Lanone S, Carreras M, Aubier M, Poderoso J. Peroxynitrite-mediated mitochondrial dysfunction. Biol Signals Recept. 2001;10:66–80.PubMedCrossRefGoogle Scholar
108. 108.
     Hambrecht R, Adams V, Gielen S, Linke A, Mobius-Winkler S, Yu J, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999;33(1):174–9.PubMedCrossRefGoogle Scholar
109. 109.
     Evangelista AM, Kohr MJ, Murphy E. S-nitrosylation: specificity, occupancy, and interaction with other post-translational modifications. Antioxid Redox Signal. 2013;19(11):1209–19.PubMedPubMedCentralCrossRefGoogle Scholar
110. 110.
     Velasquez DA, Martinez G, Romero A, Vazquez MJ, Boit KD, Dopeso-Reyes IG, et al. The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes. 2011;60(4):1177–85.PubMedPubMedCentralCrossRefGoogle Scholar
111. 111.
     Moon Y, Cao Y, Zhu J, Xu Y, Balkan W, Buys ES et al. GSNOR deficiency enhances in situ skeletal muscle strength, fatigue resistance and RyR1 S-nitrosylation without impacting mitochondrial content and activity. Antioxid Redox Signal. 2016.Google Scholar
112. 112.
     Piantadosi CA. Regulation of mitochondrial processes by protein S-nitrosylation. Biochim Biophys Acta. 2012;1820(6):712–21.PubMedCrossRefGoogle Scholar
113. 113.
     Albertini M, Lafortuna C, Aguggini G. Effects of nitric oxide on diaphragmatic muscle endurance and strength in pigs. Exp Physiol. 1997;82(1):99–106.PubMedCrossRefGoogle Scholar
114. 114.
     Belia S, Pietrangelo T, Fulle S, Menchetti G, Cecchini E, Felaco M, et al. Sodium nitroprusside, a NO donor, modifies Ca2+ transport and mechanical properties in frog skeletal muscle. J Muscle Res Cell Motil. 1998;19(8):865–76.PubMedCrossRefGoogle Scholar
115. 115.
     Zhou LZ, Johnson AP, Rando TA. NF kappa B and AP-1 mediate transcriptional responses to oxidative stress in skeletal muscle cells. Free Radic Biol Med. 2001;31(11):1405–16.PubMedCrossRefGoogle Scholar
116. 116.
     Haldar SM, Stamler JS. S-nitrosylation: integrator of cardiovascular performance and oxygen delivery. J Clin Invest. 2013;123(1):101–10.PubMedPubMedCentralCrossRefGoogle Scholar
117. 117.
     Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6(2):150–66.PubMedCrossRefGoogle Scholar
118. 118.
     Wu C, Liu T, Chen W, Oka S, Fu C, Jain MR, et al. Redox regulatory mechanism of transnitrosylation by thioredoxin. Molec Cell Proteomics : MCP. 2010;9(10):2262–75.CrossRefGoogle Scholar
119. 119.
     Dodd SL, Gagnon BJ, Senf SM, Hain BA, Judge AR. Ros-mediated activation of NF-kappaB and Foxo during muscle disuse. Muscle Nerve. 2010;41(1):110–3.PubMedPubMedCentralCrossRefGoogle Scholar
120. 120.
     Derbre F, Ferrando B, Gomez-Cabrera MC, Sanchis-Gomar F, Martinez-Bello VE, Olaso-Gonzalez G, et al. Inhibition of xanthine oxidase by allopurinol prevents skeletal muscle atrophy: role of p38 MAPKinase and E3 ubiquitin ligases. PLoS One. 2012;7(10):e46668.PubMedPubMedCentralCrossRefGoogle Scholar
121. 121.
     Kroller-Schon S, Jansen T, Hauptmann F, Schuler A, Heeren T, Hausding M, et al. alpha1AMP-activated protein kinase mediates vascular protective effects of exercise. Arterioscler Thromb Vasc Biol. 2012;32(7):1632–41.PubMedCrossRefGoogle Scholar
122. 122.
     McArdle F, Spiers S, Aldemir H, Vasilaki A, Beaver A, Iwanejko L, et al. Preconditioning of skeletal muscle against contraction-induced damage: the role of adaptations to oxidants in mice. J Physiol. 2004;561(Pt 1):233–44.PubMedPubMedCentralCrossRefGoogle Scholar
123. 123.
     Morgan M, Liu Z. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res. 2011;21:103–15.PubMedCrossRefGoogle Scholar
124. 124.
     Cobley JN, Bartlett JD, Kayani A, Murray SW, Louhelainen J, Donovan T, et al. PGC-1alpha transcriptional response and mitochondrial adaptation to acute exercise is maintained in skeletal muscle of sedentary elderly males. Biogerontology. 2012;13(6):621–31.PubMedCrossRefGoogle Scholar
125. 125.
     Wright DC, Han DH, Garcia-Roves PM, Geiger PC, Jones TE, Holloszy JO. Exercise-induced mitochondrial biogenesis begins before the increase in muscle PGC-1alpha expression. J Biol Chem. 2007;282(1):194–9.PubMedCrossRefGoogle Scholar
126. 126.
     Hawley JA, Lessard SJ. Exercise training-induced improvements in insulin action. Acta physiologica (Oxford, England). 2008;192(1):127–35.CrossRefGoogle Scholar
127. 127.
     Olesen J, Kiilerich K, Pilegaard H. PGC-1alpha-mediated adaptations in skeletal muscle. Pflugers Arch - Eur J Physiol. 2010;460(1):153–62.CrossRefGoogle Scholar
128. 128.
     Koves TR, Li P, An J, Akimoto T, Slentz D, Ilkayeva O, et al. Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem. 2005;280(39):33588–98.PubMedCrossRefGoogle Scholar
129. 129.
     Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98(1):115–24.PubMedCrossRefGoogle Scholar
130. 130.
     Marshall HE, Hess DT, Stamler JS. S-nitrosylation: physiological regulation of NF-kappaB. Proc Natl Acad Sci U S A. 2004;101(24):8841–2.PubMedPubMedCentralCrossRefGoogle Scholar
131. 131.
     Numajiri N, Takasawa K, Nishiya T, Tanaka H, Ohno K, Hayakawa W, et al. On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN). Proc Natl Acad Sci U S A. 2011;108(25):10349–54.PubMedPubMedCentralCrossRefGoogle Scholar
132. 132.
     Kelleher ZT, Matsumoto A, Stamler JS, Marshall HE. NOS2 regulation of NF-kappaB by S-nitrosylation of p65. J Biol Chem. 2007;282(42):30667–72.PubMedCrossRefGoogle Scholar
133. 133.
     Qi SH, Hao LY, Yue J, Zong YY, Zhang GY. Exogenous nitric oxide negatively regulates the S-nitrosylation p38 mitogen-activated protein kinase activation during cerebral ischaemia and reperfusion. Neuropathol Appl Neurobiol. 2013;39(3):284–97.PubMedCrossRefGoogle Scholar
134. 134.
     Nunez M, Fernandez-Sola J, Nunez E, Fernandez-Huerta JM, Godas-Sieso T, Gomez-Gil E. Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up. Clin Rheumatol. 2011;30(3):381–9.PubMedCrossRefGoogle Scholar
135. 135.
     Twisk FN, Maes M. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME) / chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett. 2009;30(3):284–99.PubMedGoogle Scholar